Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rel-MD
Baltimore, Maryland, United States
- Ownership
- Private
- Employees
- ~2
01
Overview
Rel-MD was a preclinical-stage biotechnology company focused on developing small molecule transcription factor inhibitors for the treatment of cancer and inflammatory diseases. Spun out from Profectus BioSciences in 2011, the company's research centered on targeting Rel proteins, which are members of the NF-κB family. Its lead candidate, REM-1086 (also known as PBS-1086), was designed to inhibit all five Rel proteins to block both canonical and non-canonical NF-κB pathways. The company was developing REM-1086 for multiple myeloma and was also working on prodrug formulations to improve oral bioavailability. Rel-MD ceased operations around 2017.
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Rel-MD.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rel-MD.